Co-occurrence of IgE and IgG autoantibodies in patients with chronic spontaneous urticaria.


Journal

Clinical and experimental immunology
ISSN: 1365-2249
Titre abrégé: Clin Exp Immunol
Pays: England
ID NLM: 0057202

Informations de publication

Date de publication:
06 2020
Historique:
received: 13 12 2019
revised: 04 02 2020
accepted: 26 02 2020
pubmed: 3 3 2020
medline: 21 10 2020
entrez: 3 3 2020
Statut: ppublish

Résumé

Chronic spontaneous urticaria (CSU) pathogenesis shows a complex and still unclear interplay between immunoglobulin (Ig)G- and IgE-mediated autoimmunity, leading to mast cell and basophil degranulation and wheal formation. The objective of this study was to evaluate at the same time IgE- and IgG-reactivity to well recognized and recently reported autoantigens in CSU patients, and to assess the effects of such reactivity on response to the anti-IgE monoclonal antibody omalizumab. Twenty CSU patients underwent omalizumab treatment. Urticaria activity score 7 (UAS7) was recorded at baseline and at different drug administration time-points for categorizing early-, late- or non-responders. At baseline, sera from the 20 patients and from 20 controls were tested for IgE and IgG autoantibodies to high- and low-affinity IgE receptors (FcεRI and FcεRII), tissue factor (TF) and thyroglobulin (TG) by immunoenzymatic methods. Antibody levels were compared with those of controls and analysed according to response. Eighteen patients were omalizumab responders (11 early and seven late), while two were non-responders. More than 50% of patients had contemporary IgE and IgG to at least to one of the four different autoantigens. Late responders showed higher levels of both anti-TF IgE and IgG than early responders (P = 0·011 and P = 0·035, respectively). Twenty-five per cent of patients had levels of anti-FcεRI IgE, exceeding the upper normal limit, suggesting that it could be a novel auto-allergen in CSU. In CSU, there is an autoimmune milieu characterized by the co-existence of IgE and IgG autoantibodies to the same antigen/allergen, particularly in late responders to omalizumab, possibly explaining the slower response.

Identifiants

pubmed: 32115683
doi: 10.1111/cei.13428
pmc: PMC7231996
doi:

Substances chimiques

Autoantibodies 0
Autoantigens 0
FCER2 protein, human 0
Immunoglobulin G 0
Lectins, C-Type 0
Receptors, IgE 0
Omalizumab 2P471X1Z11
Immunoglobulin E 37341-29-0
Thyroglobulin 9010-34-8
Thromboplastin 9035-58-9

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

242-249

Informations de copyright

© 2020 British Society for Immunology.

Références

J Clin Invest. 1995 Dec;96(6):2606-12
pubmed: 8675625
Acta Derm Venereol. 2017 Jun 9;97(6):698-704
pubmed: 28303277
J Allergy Clin Immunol. 2017 Mar;139(3):1059-1061.e1
pubmed: 27838346
Clin Exp Allergy. 1991 Nov;21(6):695-704
pubmed: 1723343
PLoS One. 2011 Apr 12;6(4):e14794
pubmed: 21532759
J Invest Dermatol. 1988 Feb;90(2):213-7
pubmed: 2448392
J Allergy Clin Immunol. 2018 Sep;142(3):876-882
pubmed: 29208545
J Allergy Clin Immunol. 1989 Jul;84(1):66-71
pubmed: 2754146
J Allergy Clin Immunol. 2018 Jun;141(6):2313-2316.e1
pubmed: 29518420
Eur J Immunol. 2018 Dec;48(12):2005-2014
pubmed: 30252930
Allergy. 2018 Dec;73(12):2406-2408
pubmed: 30076605
J Eur Acad Dermatol Venereol. 2019 May;33(5):918-924
pubmed: 30451325
Int Arch Allergy Immunol. 2009;148(2):170-4
pubmed: 18802362
J Allergy Clin Immunol Pract. 2016 May-Jun;4(3):529-30
pubmed: 26725153
Allergy. 2018 Mar;73(3):705-712
pubmed: 29083482
Allergy. 2018 Dec;73(12):2408-2411
pubmed: 30076634
Allergol Int. 2018 Apr;67(2):191-194
pubmed: 28993062
N Engl J Med. 1993 Jun 3;328(22):1599-604
pubmed: 7683772
Expert Rev Clin Immunol. 2016;12(3):229-31
pubmed: 26630120
Allergy. 2018 Jul;73(7):1393-1414
pubmed: 29336054
Clin Exp Allergy. 2005 Dec;35(12):1599-607
pubmed: 16393326
Br J Dermatol. 2018 Sep;179(3):776-777
pubmed: 29582427
J Microbiol Immunol Infect. 2020 Feb;53(1):141-147
pubmed: 29169972

Auteurs

R Asero (R)

Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.

A V Marzano (AV)

UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.

S Ferrucci (S)

UOC Dermatologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

M Lorini (M)

Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy.

V Carbonelli (V)

Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy.

M Cugno (M)

Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano, Milan, Italy.
Medicina Interna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH